![John S. Hoffer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Storia della carriera di John S. Hoffer
Precedenti posizioni note di John S. Hoffer
Società | Posizione | Inizio | Fine |
---|---|---|---|
SyntheMed, Inc.
![]() SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | Consigliere Generale | 01/09/2005 | 16/09/2011 |
Formazione di John S. Hoffer
Fairleigh Dickinson University | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 3 |
Posizioni
General Counsel | 1 |
Graduate Degree | 1 |
Undergraduate Degree | 1 |
Settori
Health Technology | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
SyntheMed, Inc.
![]() SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | Health Technology |
- Borsa valori
- Insiders
- John S. Hoffer
- Esperienza